John M. Timmerman - Researcher Profile

Publications

3 shown

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang , Javier Muñoz , André Goy +22 more

KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that...

2020 New England Journal of Medicine 1666 citations

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell , Alexander M. Lesokhin , Ivan Borrello +16 more

Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chro...

2014 New England Journal of Medicine 3484 citations

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke , Armin Ghobadi , Caron A. Jacobson +28 more

2018 The Lancet Oncology 2108 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 7,258
Institution: University of California, Los Angeles

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-4104-8943

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.